Manchester, United Kingdom

Romina Girotti


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Romina Girotti: Innovator in Cancer Therapeutics

Introduction

Romina Girotti is a prominent inventor based in Manchester, GB. She has made significant contributions to the field of therapeutic compounds, particularly in the development of innovative treatments for cancer. With a total of two patents to her name, her work is paving the way for advancements in cancer therapy.

Latest Patents

Romina's latest patents focus on 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer. These compounds, referred to as 'TBAP compounds', are designed to inhibit RAF proteins such as BRAF and CRAF. The invention encompasses pharmaceutical compositions that utilize these compounds to treat various disorders, including malignant melanoma, colorectal carcinoma, and pancreatic adenocarcinoma, among others.

Career Highlights

Throughout her career, Romina has worked with notable organizations, including Cancer Research Technology Limited and the Institute of Cancer Research. Her research has focused on developing therapeutic solutions that address critical health challenges associated with cancer and other proliferative disorders.

Collaborations

Romina has collaborated with esteemed colleagues in her field, including Caroline Joy Springer and Richard Marais. These partnerships have enhanced her research and contributed to the advancement of cancer treatment methodologies.

Conclusion

Romina Girotti's innovative work in cancer therapeutics exemplifies her commitment to improving patient outcomes through scientific research. Her patents and collaborations reflect her significant impact on the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…